Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
108.69
+1.41 (1.31%)
At close: Aug 1, 2025, 4:00 PM
110.00
+1.31 (1.21%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Insmed Revenue
Insmed had revenue of $92.82M in the quarter ending March 31, 2025, with 22.94% growth. This brings the company's revenue in the last twelve months to $381.03M, up 20.77% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$381.03M
Revenue Growth
+20.77%
P/S Ratio
49.10
Revenue / Employee
$299,788
Employees
1,271
Market Cap
20.65B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
INSM News
- 2 days ago - Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. - Barrons
- 9 days ago - Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 - PRNewsWire
- 6 weeks ago - Is Insmed Stock Overvalued After The 45% Jump? - Forbes
- 7 weeks ago - Insmed Announces Pricing of $750 Million Public Offering of Common Stock - PRNewsWire
- 7 weeks ago - Insmed Announces Proposed $650 Million Public Offering of Common Stock - PRNewsWire
- 7 weeks ago - Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast - Benzinga
- 7 weeks ago - Insmed: Company Presses On With Further POC PAH Treatment Data - Seeking Alpha
- 7 weeks ago - Insmed's blood pressure drug meets main goal in mid-stage trial - Reuters